10.36
전일 마감가:
$10.33
열려 있는:
$10.4
하루 거래량:
455.80K
Relative Volume:
0.71
시가총액:
$557.68M
수익:
$217.25M
순이익/손실:
$-50.92M
주가수익비율:
-10.36
EPS:
-1
순현금흐름:
$-100.85M
1주 성능:
-6.41%
1개월 성능:
-4.52%
6개월 성능:
+104.34%
1년 성능:
-24.98%
Prothena Corporation Plc Stock (PRTA) Company Profile
명칭
Prothena Corporation Plc
전화
011-353-1-236-2500
주소
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
PRTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
PRTA
Prothena Corporation Plc
|
10.36 | 556.06M | 217.25M | -50.92M | -100.85M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-05-27 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-05-27 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-27 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-01-30 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-04-24 | 개시 | SVB Securities | Outperform |
| 2023-01-27 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-09-28 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-11-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-06-18 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-06-08 | 재확인 | Oppenheimer | Outperform |
| 2021-05-26 | 개시 | Citigroup | Buy |
| 2021-02-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-02-12 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2020-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-11-19 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-05-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-04-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-04-05 | 재확인 | Barclays | Overweight |
| 2017-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2017-09-29 | 재확인 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2017-04-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-04-12 | 개시 | Piper Jaffray | Overweight |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-12-21 | 개시 | SunTrust | Buy |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-08-04 | 재확인 | Barclays | Overweight |
| 2016-05-13 | 개시 | Barclays | Overweight |
| 2016-02-19 | 재확인 | Wedbush | Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Outperform |
모두보기
Prothena Corporation Plc 주식(PRTA)의 최신 뉴스
Birchview Capital LP Has $2.74 Million Stock Holdings in Prothena Corporation plc $PRTA - MarketBeat
Prothena Board Member Paula Cobb Resigns - TipRanks
Paula Cobb steps down from Prothena’s board to join Manifold Bio By Investing.com - Investing.com South Africa
Paula Cobb steps down from Prothena’s board to join Manifold Bio - Investing.com Australia
Prothena Announces Board of Directors Update - Business Wire
What analysts say about Prothena Corporation plc stockMean Reversion Trades & Free Harness Proven Investment Plans - earlytimes.in
Prothena Corporation plc $PRTA Shares Bought by Federated Hermes Inc. - MarketBeat
Liquidity Mapping Around (PRTA) Price Events - news.stocktradersdaily.com
Ready to Jump After Recent Trade: Prothena Corporation plc (PRTA) - setenews.com
Prothena (PRTA) price target increased by 10.91% to 20.74 - MSN
How the Narrative Surrounding Prothena Is Changing After New Pipeline and Valuation Updates - Yahoo Finance
Prothena (PRTA) Price Target Increased by 10.91% to 20.74 - Nasdaq
Will Prothena Corporation plc stock outperform international peersTrade Entry Summary & Breakout Confirmation Trade Signals - Newser
Prothena (NASDAQ:PRTA) Stock Price Up 7.4%Here's Why - MarketBeat
Are Smart Investors Making the Right Decision? Prothena Corporation plc (PRTA) - setenews.com
Prothena Corp (PRTA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Citizens Jmp Forecasts Strong Price Appreciation for Prothena (NASDAQ:PRTA) Stock - MarketBeat
Prothena (NASDAQ:PRTA) Price Target Raised to $19.00 at Citizens Jmp - Defense World
Prothena stock price target raised to $19 from $11 at Citizens - Investing.com Nigeria
Prothena stock price target raised to $19 from $11 at Citizens By Investing.com - Investing.com South Africa
Citizens Raises Price Target for Prothena Corp (PRTA) to $19.00 - GuruFocus
Prothena Corporation plc Stock Analysis and ForecastFundamental Stock Analysis & Double Digit Portfolio Growth - earlytimes.in
Why (PRTA) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Aug PreEarnings: Why Prothena Corporation plc stock remains undervaluedRecession Risk & Target Return Focused Stock Picks - BỘ NỘI VỤ
DCF Advisers LLC Lowers Stock Position in Prothena Corporation plc $PRTA - MarketBeat
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Prothena (NASDAQ:PRTA) Raised to "Strong-Buy" at Chardan Capital - MarketBeat
Prothena (NASDAQ:PRTA) Upgraded at Chardan Capital - Defense World
How Prothena Corporation plc stock performs during Fed tightening cyclesJuly 2025 Reactions & Low Risk Entry Point Guides - newser.com
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 - BioSpace
Will Prothena Corporation plc stock see PE expansionQuarterly Growth Report & Free Reliable Trade Execution Plans - newser.com
Prothena Shareholders Approve Capital Reduction Proposal - TipRanks
Prothena presents TDP-43 CYTOPE data showing promise for ALS treatment - Investing.com Australia
Prothena (PRTA) Highlights Breakthrough in Drug Delivery at Neur - GuruFocus
Prothena announces poster presentation on its TDP-43 Cytope® program at neuroscience 2025 - MarketScreener
Prothena Announces Poster Presentation On Its TDP-43 Cytope® Program At Neuroscience 2025 - TradingView
What’s the recovery path for long term holders of Prothena Corporation plcPortfolio Growth Summary & Weekly Top Gainers Alerts - newser.com
Will Prothena Corporation plc stock see insider buyingWeekly Trend Summary & Community Shared Stock Ideas - newser.com
Understanding Momentum Shifts in (PRTA) - news.stocktradersdaily.com
Will Prothena Corporation plc stock maintain momentum in 2025 - newser.com
Market reaction to Prothena Corporation plc’s recent newsWeekly Market Summary & Fast Entry High Yield Tips - newser.com
What MACD and RSI say about Prothena Corporation plcTrade Performance Summary & Community Verified Watchlist Alerts - newser.com
Prothena Corporation Plc (PRTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prothena Corporation Plc 주식 (PRTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
| EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
| SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
| SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
| SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
| SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
자본화:
|
볼륨(24시간):